Background {#s1}
==========

Traumatic injuries with hemorrhage are the leading cause of potentially survivable death in both the military and civilian sectors.[@R1] The goal of initial prehospital hemorrhage control and resuscitative measures is to stop bleeding when possible, determine patient status, and delay progression into irreversible shock by providing intravenous fluids sparingly, to partially restore the patient's hemodynamics until definitive surgical control can be achieved.[@R3] The current Tactical Combat Casualty Care (TCCC) Clinical Practice Guideline (CPG) for the prehospital (Role 1 and Role 2) treatment of casualties in shock, without traumatic brain injury, is to resuscitate until a palpable radial pulse is restored, mental status is improved, or a 'permissively hypotensive' systolic blood pressure (SBP) of 85±5 mm Hg is present, preferably with blood products.[@R7] If these criteria are met, resuscitation should pause. Implementation of this hypotensive resuscitation within the 'golden hour' has improved casualty survival in recent conflicts.[@R11]

Future conflicts are predicted to occur in more resource-constrained environments, not conducive to 'golden hour' medical planning or its preferred resuscitative methods. A prolonged field care (PFC) strategy is anticipated to be required for casualty care over extended durations, up to 72 hours. Hypotensive resuscitation acutely reduces risk of clot rupture at the site of vascular injury and maintains perfusion to vital organs while decreasing risk of death from hemorrhage.[@R9] However, it is well established that sustained hypotension will consume and eventually deplete an individual's compensatory reserve to the point that vital organ perfusion is compromised, especially the brain.[@R13] While cerebral blood flow (CBF) is affected, it is generally maintained, at least over the short term, by activation of compensatory mechanisms and preserved by cerebral autoregulation. Still, many studies have demonstrated that prolonged hypotension impairs cerebral autoregulation and reduces CBF and/or oxygenation to critical brain regions.[@R14]

The aim of this study was to improve our current understanding of the implications and limitations of PFC permissive hypotensive resuscitation. We hypothesize that a strategy of 6 hours of permissive hypotension (PH) after severe decompensated hemorrhage will lead to clinically acceptable outcomes, as evidenced by physiologic and neurologic parameters.

Materials and methods {#s2}
=====================

Preoperative preparation {#s2-1}
------------------------

Fifteen male Yorkshire/Landrace swine (*Sus scrofa domesticus*) weighing 70--90 kg were randomized into three experimental groups: (1) anesthesia sham (non-shock/normotensive (NS/NT), n=5); (2) hypotensive sham (NS/PH, n=5); or (3) decompensated hemorrhage+hypotension (Decomp/PH, n=5). Male swine were used in this protocol because males comprise the majority of battlefield injuries, and regardless of species, exhibit more deleterious complications and higher mortality trauma and hemorrhage than females.[@R21]

Animals were sedated with tiletamine/zolazepam (6.0 mg/kg; Fort Dodge Animal Health, Overland Park, KS), premedicated with analgesic (buprenorphine HCl 0.01 mg/kg; Reckitt & Colman Pharmaceuticals, Richmond, VA), and intubated for ventilation and anesthesia, maintained on 1% to 3% isoflurane. Core body temperature was monitored via rectal temperature probe and maintained between 36.0°C and 38.0°C.

Four catheters were placed percutaneously. Briefly, a femoral venous catheter (8Fr; Arrow, Morrisville, NC) for fluid infusion, and a jugular vein triple lumen catheter (7Fr; Cook Medical, Bloomington, IN) for central venous pressure monitoring and continuous infusion anesthesia. Femoral arteries were cannulated with either 8Fr catheter for hemorrhage or 5Fr catheter (Cook Medical) for blood pressure (BP) monitoring and sampling. Additionally, a urinary bladder catheter (14 G needle or pediatric Foley catheter) was placed percutaneously to characterize urine output.

Hemorrhagic shock {#s2-2}
-----------------

After baseline (BSLN) blood samples were drawn, hemorrhage was initiated by free-flow of arterial blood until mean arterial pressure (MAP) reached 30 mm Hg. Additional blood was withdrawn to maintain a MAP of 30--35 mm Hg. End of shock (EOS) was defined as the animal being unable to maintain MAP \>30 mm Hg for 10 minutes. Hemorrhaged blood was collected in a blood donor bag containing anticoagulant citrate phosphate dextrose adenine solution at a 1:10 ratio for subsequent resuscitation.

To establish BSLN data and segregate effects of anesthesia alone, animals in NS/NT and NS/PH (sham groups) were maintained at NT levels (MAP≥70 mm Hg) during a 30-minute simulated shock period by administering supplemental fluid (lactated Ringer's solution; LR) in the absence of hemorrhage.

Prolonged field care {#s2-3}
--------------------

At EOS, the 6-hour PFC resuscitation phase commenced. Isoflurane was gradually reduced to 0.4% to 0.5%, as intravenous combination of propofol (3--10 mg/kg/h) and buprenorphine (2--8 µg/kg/h) started. Resuscitation commenced for Decomp/PH according to current TCCC guidelines, assuming absence of whole blood or blood component availability. Briefly, two 500 mL LR boluses were administered, followed by LR at a continuous rate to target SBP of 85±5 mm Hg. Hypotension was induced in NS/PH during the PFC period by discontinuing supplemental fluids and removing blood to a target SBP of 85±5 mm Hg. For both PH groups, if animals dropped below or climbed above the target range of 85±5 mm Hg, LR was infused or blood was removed, respectively, to maintain SBP range.

Resuscitation {#s2-4}
-------------

At the end of PFC (END PFC), animals entered a simulated 2-hour hospital phase. Anesthesia was returned to 1% to 3% isoflurane, with cessation of intravenous anesthesia. Decomp/PH animals were resuscitated to MAP\>70 mm Hg by autologous transfusion of 100% shed blood, intravenously infused over 30 minutes using a Belmont Rapid Infuser (Belmont Instrument, Billerica, MA). Calcium gluconate (10--15 mL; 23% solution; 2.14 g Ca^2+^/100 mL) was intravenously infused immediately prior to reinfusion of shed blood to counteract anticoagulant. Additional resuscitation maintenance fluid (LR) was infused, per TCCC guidelines, at 6 mL/h for the first 20 kg and an additional 1 mL/kg/h, over the final 90 minutes of hospital care to maintain MAP \>70 mm Hg.

NS/NT and NS/PH groups received maintenance fluids as described Decomp/PH for the full hospital phase. Buprenorphine Sustained-Release (0.06--0.2 mg/kg) subcutaneous was administered 30 minutes prior to the end of hospital care (EHC) to assure all animals received excellent pain control during the 24-hour survival period.

Recovery and euthanasia {#s2-5}
-----------------------

At EHC, all instrumentation was removed before recovering animals. Animals were transferred to a recovery pen and observed for 24 hours, with buprenorphine HCl (0.01--0.03 mg/kg) intramuscular, as deemed necessary by veterinarian for acute pain. Animals were monitored by veterinarian hourly for general condition and every 4 hours for pain management. After the 24-hour recovery period, animals underwent a neurological assessment adapted from Alam *et al*,[@R23] before being sedated as described in Preoperative preperation, and final blood draws taken. Swine were then humanely euthanized with pentobarbital sodium and phenytoin sodium (Euthasol, 390 mg/mL, Virbac, Fort Worth, TX, USA).

Blood draws and laboratory analysis {#s2-6}
-----------------------------------

Whole blood was collected at BSLN, EOS, PFC (hour) 1, 2, 4, END PFC, EHC, and Final. Arterial blood gas parameters were assessed using a GEM Premier 4000 (Instrumentation Laboratory, Bedford, MA). Basic metabolic panels and liver-associated enzymes were evaluated on Catalyst One Chemistry Analyzers (IDEXX Laboratories, Westbrook, ME).

Cerebrospinal fluid {#s2-7}
-------------------

Cerebrospinal fluid (CSF) was collected during necropsy and analyzed via enzyme-linked immunosorbent assay (Elabscience Biotechnology, Houston, TX) for S100 calcium-binding protein B (S100B), glial fibrillary acidic protein (GFAP), and neuron-specific enolase (NSE).

Pathology/histology {#s2-8}
-------------------

At time of euthanasia, necropsy was performed to collect representative sections of brain (hippocampus, cerebellum, frontal cortex), heart, lungs, liver, kidney, spleen, ileum, adrenal glands, and mesenteric lymph nodes for histopathologic evaluation. Tissue sections were fixed and stained with H&E, and then examined by a veterinarian pathologist blinded to the experimental groups, using an Olympus BX51 upright brightfield microscope (Olympus Scientific Solutions, Waltham, MA). Tissues were scored for severity of pathology as detailed below (table 4).

Data and statistical analysis {#s2-9}
-----------------------------

Statistical analyses were performed using Prism V.7 (GraphPad Software, La Jolla, CA). Data are presented as mean±SD. Single time point analyses were performed by one-way analysis of variance (ANOVA) with Tukey's post hoc, and multiple time point analyses were analyzed by two-way repeated measures ANOVA with Bonferroni correction post hoc analysis. Neurocognitive and histological assessment scores were analyzed via Kruskal-Wallis test with Dunn's multiple comparisons post hoc test. P values \<0.05 were considered to be statistically significant. A priori and post hoc power analyses were performed using G\*Power V.3.1 Statistical Power Analysis program (Heinrich Heine Universitat, Dusseldorf, Germany), to determine power for neurocognitive scores, lactate, pH, bicarbonate (HCO~3~), base excess (BE), and aspartate aminotransferase (AST). With 100% survival across all three groups and analyses showing average power calculations of 0.88, it was determined that sufficient group sizes were met to answer the hypothesis with a large effect size.

Results {#s3}
=======

Demographics, blood loss, fluid volumes, and survival {#s3-1}
-----------------------------------------------------

There were no significant differences in age or weight between groups. Experimental timeline occurred as shown in [figure 1A](#F1){ref-type="fig"}. The mean time until decompensation for the decompensated hemorrhage+hypotension group (Decomp/PH) was 67.6±23.1 minutes, with a mean volume per weight blood loss of 34.4±3.1 mL/kg. Decomp/PH and sham groups (anesthesia sham=NS/NT, hypotensive sham=NS/PH) demonstrated 100% survival (data not shown). As Decomp/PH was unable to achieve and maintain targeted SBP of 85±5 mm Hg, continuous infusion of crystalloid throughout PFC resulted in significantly higher fluid volumes than sham groups (2.1±4.6 vs. 17.3±8.0 vs. 78.1±8.9 mL/kg).

![Timeline and vitals. (A) Schematic depicting experimental timeline, with time points running from instrumentation, through hemorrhage, prolonged field care, hospital care, postoperative observation and euthanasia. Blood draws were obtained at each indicated time point for labs (arterial blood gas and serum chemistries) at baseline (BSLN), end of shock (EOS), prolonged field care (PFC1), PFC2, PFC4, END PFC, end of hospital care (EHC) and euthanasia (Final). Vitals were continuously monitored throughout the operational stages of the protocol. Data are presented as mean±SD for (B) mean arterial pressure (MAP), (C) systolic blood pressure (SBP), and (D) heart rate. Lines indicate groups: group 1 (NS/NT, n=5, solid line); group 2 (NS/PH, n=5, dashed line); group 3 (Decomp/PH, n=5, dashed/dotted line). P values \<0.05 were considered to be statistically significant. Significant differences between groups are indicated as: \*NS/NT versus NS/PH, †NS/NT versus Decomp/PH, \#NS/PH versus Decomp/PH, \$NS/NT versus BSLN, ‡NS/PH versus BSLN, &Decomp/PH versus BSLN. BPM, beats per minute; END PFC, end of prolonged field care; HR, heart rate; NS, non-shock; NT, normotensive; PH, permissive hypotension](tsaco-2019-000369f01){#F1}

Hemodynamics, heart rate, and respiratory function {#s3-2}
--------------------------------------------------

Hemodynamics were equivalent between all groups at BSLN. At EOS, Decomp/PH MAP was significantly lower (37.3±4.2 mm Hg) compared with BSLN (65.7±3.2 mm Hg) and sham groups (NS/NT: 69.5±0.7, NS/PH: 76.7±10.7 mm Hg) ([figure 1B](#F1){ref-type="fig"}). SBP was significantly lower than NS/NT from PFC1 through PFC4 ([figure 1C](#F1){ref-type="fig"}). Mean SBPs over PFC were 109.2±12.3 (NS/NT), 87.7±1.6 (NS/PH), and 69.7±4.3 (Decomp/PH) mm Hg. While Decomp/PH demonstrated lower mean SBPs than NS/PH through PFC, this difference was not significant. Decomp/PH demonstrated significant tachycardia in response to hemorrhage compared with BSLN through END EHC and compared with sham groups through END PFC ([figure 1D](#F1){ref-type="fig"}). At EHC, all changes in BPs and heart rate between groups resolved, with no persistent significant differences.

End-tidal carbon dioxide was significantly lower in hemorrhaged groups compared with BSLN at EOS (data not shown). These differences resolved during PFC and remained equivalent to BSLN in all groups. In all groups, the PaO~2~/FiO~2~ ratio remained above 300 throughout (data not shown).

Arterial blood gas {#s3-3}
------------------

Severity of shock was evaluated via multiple parameters ([table 1](#T1){ref-type="table"}), including lactate, pH, BE and HCO~3~. At EOS, Decomp/PH demonstrated significant differences in levels of all shock parameters compared with sham groups. Differences in pH were resolved by END PFC, and all other parameters of shock resolved after hospital resuscitation ([table 1](#T1){ref-type="table"}).

###### 

Arterial gas parameters

                         NS/NT         NS/PH         Decomp/PH
  ---------------------- ------------- ------------- -------------------
  pH                                                 
   BSLN                  7.54±0.02     7.53±0.03     7.54±0.02
   EOS                   7.57±0.04     7.49±0.02     *7.44±0.08^1^*
   PFC1                  7.54±0.07     7.51±0.05     *7.34±0.091^1,2^*
   PFC2                  7.52±0.02     7.50±0.07     *7.36±0.101^1,2^*
   PFC4                  7.56±0.03     7.51±0.04     *7.42±0.071^1,2^*
   END PFC               7.55±0.03     7.52±0.04     7.47±0.06
   EHC                   7.55±0.05     7.53±0.05     7.50±0.04
   Final                 *7.40±0.04*   *7.40±0.04*   *7.43±0.04*
  Lactate (mmol/L)                                   
   BSLN                  1.8±0.4       2.4±0.7       2.0±0.4
   EOS                   1.8±0.4       2.2±0.5       *7.8±2.91^1,2^*
   PFC1                  2.1±1.1       2.7±1.8       *10.3±3.41^1,2^*
   PFC2                  1.6±0.5       3.5±3.9       *10.7±4.31^1,2^*
   PFC4                  1.3±0.1       3.6±2.8       *8.1±4.91^1,2^*
   END PFC               1.1±0.2       2.0±0.8       4.9±3.6^1^
   EHC                   1.1±0.1       1.5±0.5       2.6±2.4
   Final                 1.5±0.3       1.1±0.3       1.2±0.5
  Base excess (mmol/L)                               
   BSLN                  13.3±1.3      12.4±1.2      12.9±0.9
   EOS                   13.6±1.6      11.7±1.2      *0.2±5.21^1,2^*
   PFC1                  12.5±2.4      11.2±2.9      *−0.46±5.01^1,2^*
   PFC2                  12.8±1.3      10.1±4.8      *0.2±6.21^1,2^*
   PFC4                  13.6±2.3      9.5±3.8       *3.3±6.41^1,2^*
   END PFC               14.0±2.2      10.7±1.4      *7.2±6.0^1^*
   EHC                   13.6±2.8      12.5±2.2      11.8±4.5
   Final                 10.2±2.3      10.8±2.1      11.2±3.3
  HCO~3~ (mmol/L)                                    
   BSLN                  37.3±1.3      36.6±1.5      36.8±0.9
   EOS                   36.9±1.5      36.4±1.6      *24.0±4.21^1,2^*
   PFC1                  36.4±1.7      35.5±2.4      *25.5±3.81^1,2^*
   PFC2                  37.0±1.3      34.3±4.1      *25.8±5.01^1,2^*
   PFC4                  37.0±2.3      33.3±3.6      *28.1±5.51^1,2^*
   END PFC               37.8±2.1      34.5±1.4      *31.4±5.5^1^*
   EHC                   37.2±2.5      36.4±2.3      35.9±4.4
   Final                 36.7±2.5      37.2±2.2      37.0±3.0

Results are presented as mean±SD. Statistical significance is achieved by p\<0.05. Values significantly different from BSLN are denoted in italics. Superscript numbers indicate value is significantly different from the corresponding column listed.

BSLN, baseline; EHC, end of hospital care; END PFC, end of prolonged field care; EOS, end of shock; NS, non-shock; NT, normotensive; PFC, prolonged field care; PH, permissive hypotension.

Neurological assessment, organ function, and histology {#s3-4}
------------------------------------------------------

No groups showed neurologic impairment prior to undergoing the protocol. After procedure, and prior to euthanasia, all animals continued to be neurologically intact. No group demonstrated any significant change in score compared with either their BSLN or sham control groups ([table 2](#T2){ref-type="table"}). Additionally, no markers of neurological damage were detected in CSF ([table 3](#T3){ref-type="table"}).

###### 

Neurological assessment outcomes

                           NS/NT   NS/PH   Decomp/PH   P value   
  ------------------------ ------- ------- ----------- --------- ----------
  Level of consciousness   0--3    0±0     0.2±0.5     0±0       \>0.9999
  Behavior                 0--3    0±0     0±0         0.4±0.6   0.2857
  Feeding/drinking         0--2    0±0     0±0         0±0       0.2857
  Standing position        0--4    0±0     0.4±0.9     0.2±0.5   \>0.9999
  Head position            0--2    0±0     0±0         0±0       NA
  Utterance                0--1    0±0     0±0         0±0       NA
  Gait                     0--3    0±0     0.8±1.3     0.2±0.5   0.5055
  Forelimb, left           0--4    0±0     0.2±0.5     0±0       \>0.9999
  Forelimb, right          0--4    0±0     0.2±0.5     0.2±0.5   \>0.9999
  Hindlimb, left           0--4    0±0     0.6±1.3     0±0       \>0.9999
  Hindlimb, right          0--4    0±0     0.6±1.3     0.4±0.9   \>0.9999
  Sum                      0--34   0±0     3.0±4.8     1.4±2.2   0.3773

Results are presented as mean±SD. Statistical significance is achieved by p\<0.05.

NA, not applicable; NS, non-shock; NT, normotensive; PH, permissive hypotension.

###### 

Organ function parameters

                  NS/NT            NS/PH           Decomp/PH
  --------------- ---------------- --------------- ---------------------
  S100B (ng/mL)   0.26±0.45        0.04±0.06       0.48±0.39
  GFAP (ng/mL)    0.00±0.00        0.10±0.18       0.00±0.00
  NSE (ng/mL)     0.12±0.27        0.00±0.00       0.19±0.42
  BUN (mg/dL)                                      
   BSLN           6.2±2.4          9.2±3.3         5.4±3.2
   EOS            6.2±2.4          9.2±3.3         7.0±3.5
   PFC1           7.4±2.1          9.8±3.4         7.2±3.6
   PFC2           8.8±2.5          11.4±3.6        *8.8±3.8*
   PFC4           *10.6±2.3*       *13.8±3.8*      *11.4±4.3*
   END PFC        *12.0±2.5*       *15.4±3.6*      *13.2±4.3*
   EHC            *13.4±2.3*       *15.0±5.5*      *11.4±3.2*
   Final          8.2±3.0          9.4±3.4         6.6±4.3
  CREA (mg/dL)                                     
   BSLN           1.3±0.2          1.3±0.2         1.0±0.2
   EOS            1.3±0.2^3^       1.3±0.2^3^      *1.3±0.11^1,2^*
   PFC1           1.2±0.2^3^       1.3±0.2^3^      *1.2±0.21^1,2^*
   PFC2           1.2±0.2^3^       1.2±0.1^3^      *1.2±0.21^1,2^*
   PFC4           1.2±0.2^3^       1.2±0.2^3^      1.1±0.2*^1,2^*
   END PFC        1.2±0.2          1.1±0.1^3^      1.0±0.1^2^
   EHC            1.1±0.2^3^       1.2±0.1^3^      1.1±0.2*^1,2^*
   Final          1.1±0.1          1.2±0.1         0.9±0.2
  AST (U/L)                                        
   BSLN           22.0±5.2         22.6±5.4        19.2±2.5
   EOS            23.8±8.2         22.6±4.9        20.6±3.4
   PFC1           22.4±4.0         23.2±7.0        36.6±15.0
   PFC2           20.4±4.3         23.4±4.9        114.6±131.0
   PFC4           25.8±8.7         27.6±8.4        296.4±375.6
   END PFC        33.8±18.6^3^     35.0±15.4^3^    *472.2±603.51^1,2^*
   EHC            42.0±22.3^3^     51.2±34.6^3^    *426.0±395.91^1,2^*
   Final          353.6±278.9^3^   *550.6±223.4*   *794.0±600.0^1^*
  ALT (U/L)                                        
   BSLN           53.0±15.2        57.2±14.7       54.4±7.9
   EOS            51.0±15.3        59.4±15.3       53.0±7.3
   PFC1           51.8±15.4        62.4±11.3       46.8±4.5
   PFC2           52.2±13.5        59.4±13.8       54.6±9.2
   PFC4           51.4±13.7        58.4±14.7       70.4±24.2
   END PFC        53.2±12.4        54.2±10.7       75.6±32.9
   EHC            53.0±12.0        57.6±13.7       88.2±18.3
   Final          *153.4±55.6*     *151.8±39.5*    *202.8±80.7*

Results are presented as mean±SD. Statistical significance is achieved by p\<0.05. Values significantly different from BSLN are denoted in italics. Superscript numbers indicate value is significantly different from the corresponding column listed.

ALT, alanine aminotransferase; AST, aspartate aminotransferase; BSLN, baseline; BUN, blood urea nitrogen; CREA, creatinine; EHC, end of hospital care; END PFC, end of prolonged field care; EOS, end of shock; GFAP, glial fibrillary acidic protein; NS, non-shock; NSE, neuron-specific enolase; NT, normotensive; PFC, prolonged field care; PH, permissive hypotension.

Kidney function was assessed by blood urea nitrogen (BUN) and creatinine (CREA; [table 3](#T3){ref-type="table"}). Compared with BSLN, BUN, NS/NT and NS/PH were significantly elevated from PFC4 through EHC, and Decomp/PH was significantly elevated from PFC2 through EHC. Decomp/PH was significantly increased from BSLN at EOS through PFC2. Fold changes of CREA were significantly higher for Decomp/PH than NS/NT from EOS through PFC4, and at EHC, and significantly higher compared with NS/PH from EOS through EHC. All groups demonstrated significant changes in BUN/CREA from BSLN at PFC4 through EHC (data not shown). BUN and BUN/CREA demonstrated no significant group effects.

Acute liver function was assessed via AST and alanine aminotransferase (ALT; [table 3](#T3){ref-type="table"}). AST levels for Decomp/PH were significantly higher than BSLN at END PFC through euthanasia. Additionally, all groups demonstrated significant increase from BSLN at euthanasia. Decomp/PH had significantly higher levels at END PFC through EHC compared with sham groups, and remained significantly higher than NS/NT at euthanasia. All groups demonstrated a significant increase in ALT from BSLN at euthanasia only, and no significant group effects were seen.

Nine different tissue samples were scored for histology. While 5 of the 31 lesion scores showed significant differences between groups, no acute markers of inflammation or organ failure were identified as having changed due to injury or treatment ([table 4](#T4){ref-type="table"}).

###### 

Histological scores

                                                  NS/NT        NS/PH          Decomp/PH      P value
  ----------------------------------------------- ------------ -------------- -------------- ----------
  Lung, cranial lobe                                                                         
   Alveolar histiocytes                           0.2±0.4      0±0            0±0            \>0.9999
   Hemorrhage                                     0.1±0.2      0±0            0.4±0.9        \>0.9999
   Pleural expansion                              0.8±0.8      0±0            0.6±0.9        0.2857
   Alveolar edema                                 0.2±0.4      1.0±1.4        0.2±0.4        0.5255
  Atelectasis                                     0±0          0.5±0.6        1.2±1.1        0.0899
   Alveolar septae fracture                       0.4±0.5      0±0            0±0            0.2857
   Congestion                                     1.0±0        1.3±0.5^3^     0.2±0.4^2^     *0.0050*
  Heart, left ventricle                                                                      
  Mineralization                                  0±0^3^       0±0^3^         0.8±0.4^1,2^   *0.0110*
   Adipose tissue on epicardium                   0.6±1.3      0.8±1.5        0±0            0.7253
   Necrosis and degeneration                      0.8±0.8      0.5±0.6        1.0±0.7        0.5810
  Ileum                                                                                      
   Crypt abscess                                  0±0          0±0            0±0            \>0.9999
   Eos/Lpcyt inflammation                         1.7±0.7      1.0±1.2        1.0±0          0.2462
   Lamina propria edema                           0±0          0.5±0.6        0±0            0.0659
  Liver                                                                                      
   Periportal inflammation                        0.2±0.4      0.8±0.5        0.4±0.5        0.3340
   Sinusoid dilation                              0.6±0.5      0.5±0.6        0±0            0.1508
   Hepatic cord atrophy                           0.2±0.4      0.3±0.5        0±0            0.7253
   Glycogenosis                                   2.6±0.^3^    2.3±1.0^3^     0±0^1,2^       *0.0015*
  Lymphoplasmacytic infiltrates                   0±0^2^       0.8±0.5^1,3^   0±0^2^         *0.0110*
  Hepatocyte necrosis                             0±0          0.3±0.5        0.6±0.9        0.3773
  Regenerative nodules                            0±0          0.3±0.5        0±0            0.2857
  Spleen                                                                                     
  Eosinophilic/neutrophilic drainage              0±0          0±0            0±0            \>0.9999
   Diffuse congestion                             2.4±1.3^3^   2.3±1.0        0±0^1^         *0.0117*
   Kidney                                                                                    
   Tubular epithelium vacuolation                 0.8±0.8      0±0            0±0            0.0659
   Interstitial congestion                        0.2±0.4      0±0            0±0            \>0.9999
   Tubular necrosis and degeneration              0.4±0.9      0±0            0±0            \>0.9999
   Proteinosis                                    0.4±0.5      0±0            0±0            0.2857
  Brain                                                                                      
  Hippocampus neuronal degeneration/necrosis      0±0          0±0            0±0            \>0.9999
  Cerebellum neuronal degeneration/necrosis       0±0          0±0            0±0            \>0.9999
  Frontal cortex neuronal degeneration/necrosis   0±0          0±0            0±0            \>0.9999
   Mesenteric lymph node                                                                     
   Eosinophilic/neutrophilic drainage             1.8±0.8      2.0±1.2        0.4±0.5        *0.0327*
   Adrenal gland                                                                             
  Lymphoplasmacytic infiltrates                   0±0          0.3±0.5        0±0            0.2857

Tissues were scored as: 0=none, 0.5=minimal, 1=mild, 2=moderate, 3=severe. Results are presented as mean±SD. Statistical significance is achieved by p\<0.05 and is denoted in italics. Superscript numbers indicate value is significantly different from the corresponding column listed.

NS, non-shock; NT, normotensive; PH, permissive hypotension.

Discussion {#s4}
==========

As future military conflicts are expected to enter more austere and resource-limited environments, it becomes increasingly necessary to understand the limitations of the 'golden hour', and how to adapt this successful short-term hemorrhage control resuscitation strategy for longer periods. As TCCC CPGs for resuscitation after hemorrhage target a hypotensive SBP of 85±5 mm Hg, we sought to determine the physiologic and neurologic limits of prolonged hypotension through initial crystalloid infusion, followed by full resuscitation with blood. Our study required a severe model of shock, as determined via hemorrhage volumes and physiologic parameters assessed.[@R24] To achieve this, we chose a pure hemorrhage, pressure-targeted model; previous work has demonstrated that even in absence of a soft tissue injury, without intervention, mortality rates of animals reach 100% within 2 hours after shock.[@R13] Additionally, while our animals were not splenectomized, several swine studies have demonstrated that splenectomy may have minimal effect on BP in response to hemorrhage, and by allowing our animals to decompensate physiologically, we exhaust the resuscitative effects of the contractile spleen.[@R24] Other studies on hypotensive resuscitation in swine using controlled hemorrhage over a 5-hour PFC demonstrate worse survival, though these models use concomitant contusions, and normal saline rather than LR.[@R29] Survival in this study at 6 hours of PFC is similar to those seen in the recent study by Skarda *et al*, which used a pure hemorrhage, pressure-targeted injury and TCCC-directed resuscitation.[@R13] However, their posthospital survival is worse, which may result from differences in recovery, as animals in their study were kept anesthetized and ventilated for 24 hours after recovery, during which time roughly 30% of their mortality occurs.

TCCC recommends blood-based resuscitation whenever possible and the recent consensus statement from the Trauma Hemostasis and Oxygenation Research Network position paper states shock in casualties with life-threatening hemorrhage should be reversed as soon as possible using a blood-based hemostatic resuscitation fluid with a target SBP of 100 mm Hg.[@R32] The authors here agree with this position, however, in a predicted military PFC scenario, limited availability of resuscitative products may be unable to achieve and maintain these desired goals. Thus, our study focused on 'pre-hospital' resuscitation, and demonstrates that hypotensive resuscitation after decompensated shock is permissible over a 6-hour period, before hospital intervention can be achieved, crucial information for the PFC environment. Critically, this methodology resulted in 100% survival, without significant neurologic impact or histological evidence of ischemic injury, neuronal degradation, or necrosis of the brain. Increasing evidence suggests that levels of S100B, NSE, and GFAP rise in the CSF before development of clinically observable brain injury.[@R33] At the point of euthanasia in this study, however, we observed no significant differences in CSF levels of any of these biomarkers.

While Decomp/PH animals developed lactatemia by EOS, this resolved by END PFC. With crystalloid resuscitation restricted to the volume necessary to achieve the resuscitation goal of SBP of 85±5 mm Hg, animals were able to maintain sufficient perfusion to avoid acidosis after 6 hours. This is also reflected in the trend of BE and HCO~3~ returning towards BSLN by END PFC and completely by EHC. The impact of this may be reflected in the severity of end-organ damage. Kidney function was maintained during the entirety of the study. While BUN and CREA increased during shock and PFC, they decreased appropriately with resuscitation. Importantly, there was no significant increase in CREA at euthanasia, 26 hours after END PFC, indicating no animals developed reduced renal clearance resulting from prolonged hypotension. Histology also demonstrated kidney preservation (eg, no tubular necrosis). Hepatic function in this model was more sensitive to ischemic injury. There was earlier rise of serum AST by the END PFC for Decomp/PH, though all groups showed a significant increase from their BSLNs over the experimental course including sham groups. Overall increase in ALT levels after recovery was independent of injury or resuscitation strategy. Despite the increase in AST and ALT, histology demonstrated no significant findings of liver damage. Across examined tissues, differences in histological scores are more reflective of crystalloid dilution than acute inflammation or organ failure.

Limitations {#s4-1}
-----------

The use of a pressure-targeted, pure hemorrhage model represents one possible limitation here. Despite lacking a soft tissue injury, blast, or other major trauma insult, models of pressure-targeted hemorrhage are still extremely useful for advancing the treatment of patients in hemorrhagic shock.[@R24] Adding an injury would undoubtedly change the profile of shock, and we thought that this model approximates our military injury population, representing a penetrating injury with significant hemorrhage, as seen in combat operations. Additionally, the PFC-targeted SBP of 85±5 mm Hg was not achieved in the hemorrhage group. While not significantly different from the NS/PH sham during PFC, lower pressure ranges may be indicative of more severe hypotension. Conversely, they may be a more accurate hypotension level given that swine models demonstrate consistently lower BPs than humans.[@R25]

Furthermore, while useful for our experimental model, large volumes of crystalloid in austere environments would represent logistical challenges, being well beyond the limited weight that individual military medics carry. The evidence of acceptable clinical outcomes under prolonged hypotension, despite large volumes of crystalloid to maintain targeted pressure, further highlights the need for development of low-volume resuscitation strategies. Future studies may also include BP adjuncts such as vasopressors to help define their role in hypotensive resuscitation.

Conclusion {#s5}
==========

We indicate here that after severe hemorrhage and decompensated shock, current standards of hypotensive resuscitation targeting SBP of 85±5 mm Hg over 6 hours can be used to achieve 100% survival, even in situations where there may be limited blood product availability. While the methodology of unlimited crystalloid is unrealistic, prolonged hypotension itself does not induce observed negative clinical outcomes related to neurologic function, brain or other organ function. This represents a partial answer to a critical gap in current knowledge, and future work will be required to describe outcomes out to 72 hours.
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